You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: April 6, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for AV-101

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug AV-101?

AV-101 is an investigational drug.

There have been 4 clinical trials for AV-101. The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2018.

The most common disease conditions in clinical trials are Dyskinesias, Dyskinesia, Drug-Induced, and Depressive Disorder, Major. The leading clinical trial sponsors are VistaGen Therapeutics, Inc., Marijn Lijffijt, PhD, and Michael Debakey Veterans Affairs Medical Center.

There are seventeen US patents protecting this investigational drug and one hundred and ninety-four international patents.

Recent Clinical Trials for AV-101
AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced DyskinesiaVistaGen Therapeutics, Inc.Phase 2
Electrophysiological Biomarkers of AV-101Michael Debakey Veterans Affairs Medical CenterPhase 1/Phase 2
Electrophysiological Biomarkers of AV-101VistaGen Therapeutics, Inc.Phase 1/Phase 2

See all AV-101 clinical trials

Clinical Trial Summary for AV-101

Top disease conditions for AV-101
Top clinical trial sponsors for AV-101

See all AV-101 clinical trials

US Patents for AV-101

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AV-101   Start Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN)   Start Trial
AV-101   Start Trial Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN)   Start Trial
AV-101   Start Trial Methods for the synthesis of chiral kynurenine compounds VISTAGEN THERAPEUTICS, INC. (South San Francisco, CA)   Start Trial
AV-101   Start Trial Compartmented pharmaceutical dosage forms Triastek, Inc. (Nanjing, CN)   Start Trial
AV-101   Start Trial NMDA antagonists Merrell Dow Pharmaceuticals Inc. (Cincinnati, OH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AV-101

Drugname Country Document Number Estimated Expiration Related US Patent
AV-101 Australia 2017261372 2036-05-05   Start Trial
AV-101 Canada 3023278 2036-05-05   Start Trial
AV-101 China 107847398 2036-05-05   Start Trial
AV-101 European Patent Office 3452003 2036-05-05   Start Trial
AV-101 Japan 2019520866 2036-05-05   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.